Search

Your search keyword '"Harrison, CJ"' showing total 627 results
Start Over Author "Harrison, CJ"

Refine your results

627 results on '"Harrison, CJ"'

1. Transforming cancer outcomes in England: earlier and faster diagnoses, pathways to success, and empowering alliances

Author

Harrison CJ, Spencer RG, and Shackley DC

Subjects
ancer – England – Alliances – Diagnosis – Rapid – Outcomes, Public aspects of medicine, RA1-1270
Abstract

Christopher J Harrison,1 Roger G Spencer,2 David C Shackley3 1University of Manchester Division of Cancer Sciences, The Christie NHS Foundation Trust, Manchester, UK; 2Chief Executive’s Office, The Christie NHS Foundation Trust, Manchester, UK; 3University of Manchester Division of Cancer Sciences, Greater Manchester Cancer, Manchester, UK Abstract: Cancer outcomes and patient experience in England have never been better but survival remains worse than in comparable countries. Differences in stage at diagnosis and, to a lesser extent, access to optimal treatments are likely to be the most important factors. The national cancer plan emphasizes earlier and faster diagnosis and the creation of cancer alliances providing strategic leadership and coordination. Earlier diagnosis is being promoted by national awareness campaigns designed to overcome fatalism and perceived barriers to consulting a general practitioner as well as improvements to existing screening programs and the introduction of more targeted screening such as Lung Health Checks. These are supported by local social marketing campaigns in which trained volunteers support and advise others about cancer and cancer care. The epidemiology of symptoms in general practice provides an organizing framework for cancer diagnostic pathways. Alliances are implementing a broader model of cancer diagnostic clinics at a larger scale taking into account the different needs of patients with 1) obvious alert symptoms, 2) low risk but not no risk symptoms, and 3) serious but not specific symptoms. Faster diagnosis is being promoted by the introduction of a Faster Diagnosis Standard requiring patients are given a diagnosis of cancer or have it ruled out within 28 days of referral. The three cancer alliances forming the National Cancer Vanguard together with NHS England are publishing clinically led evidence-based Timed Diagnostic Pathways which show how the drastic changes needed can be achieved. Cancer alliances have been successful in developing clinical cancer pathways which need support by improved commissioning and regulatory approaches which align clinical pathways with financial and performance ratings. Clinical leadership has been essential but further focus is needed on making sure that performance and regulatory approaches give proper attention and encouragement to earlier and faster diagnosis. Keywords: cancer, pathways, outcomes, vanguard, diagnosis, rapid

Published
2019

2. Nanoporous naphthalene diimide surface enhances humidity and ammonia sensing at room temperature

Author

Ali, S, Jameel, MA, Harrison, CJ, Gupta, A, Shafiei, M, Langford, SJ, Ali, S, Jameel, MA, Harrison, CJ, Gupta, A, Shafiei, M, and Langford, SJ

Abstract

We report fabrication and characterisation of humidity and ammonia sensors based on a nanoporous naphthalene diimide (NDI) thin layer, the active material coded as NDI-1, operating at room temperature. A thin layer of NDI-1 as an organic semiconducting sensing material was deposited onto the interdigitated electrodes using the spin-coating technique. Surface morphology investigations of the thin film using atomic force microscopy and scanning electronic microscopy revealed a uniform nanoporous surface. Structural and thermal behaviour studies of the NDI-1 using X-ray diffraction and thermogravimetric analyses confirmed the crystallinity and thermal stability, respectively. The capacitive type NDI-1 humidity sensor displayed a sensitivity of 10.13 pF/%RH, quick response and recovery (20.1/6.28 s), low hysteresis (0.72%), long-term stability and more importantly, a wide working range of relative humidity (10–95%) at 250 Hz. Interestingly, the developed sensor was sensitive enough to monitor respiration rate and demonstrated an excellent non-contact skin humidity sensing performance. The amperometric response of the sensor towards ammonia was also investigated. An increase in the sensor current was recorded when exposed to different ammonia concentrations (25, 37.5 and 50 ppm). The sensor showed high selectivity and good sensitivity (27.7%) towards 50 ppm ammonia with 200 s and 350 s response and recovery times, respectively.

Published
2022

4. Enhanced capacitive humidity sensing performance at room temperature via hydrogen bonding of cyanopyridone-based oligothiophene donor

Author

Ali, S, Jameel, MA, Harrison, CJ, Gupta, Akhil, Evans, RA, Shafiei, M, Langford, SJ, Ali, S, Jameel, MA, Harrison, CJ, Gupta, Akhil, Evans, RA, Shafiei, M, and Langford, SJ

Abstract

Cyanopyridone-based oligothiophene donors with both hydrophobic and hydrophilic characters have been evaluated as active layers within simple capacitive devices for humidity sensing at room temperature. Surface studies using atomic force microscopy revealed a self-assembled nanofibrous network with a thin needle-like structure for the terminal hydroxy example (CP6), devoid in the methyl example (CP1). The sensing performance of each sensor was investigated over a broad range of relative humidity levels as a function of capacitance at room temperature. The sensor CP6 demonstrated favourable features such as high sensitivity (12.2 pF/%RH), quick response/recovery (13 s/20.7 s), wide working range of relative humidity (10%–95% RH), low hysteresis (0.57%), outstanding recyclability, and excellent long-term stability. From the results obtained, hydrophilicity and hydrogen bonding appear to play a vital role in enhancing humidity sensing performance, leading to possible new design directions for simple organic semiconductor-based sensors.

Published
2021

5. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Author

Newman, AM, Zaka, M, Zhou, P, Blain, AE, Erhorn, A, Barnard, A, Crossland, RE, Wilkinson, S, Enshaei, A, De Zordi, J, Harding, F, Taj, M, Wood, KM, Televantou, D, Turner, SD, Burke, GAA, Harrison, CJ, Bomken, S, Bacon, CM, Rand, V, Blain, AE [0000-0001-8045-822X], Turner, SD [0000-0002-8439-4507], Burke, GAA [0000-0003-2671-9972], Rand, V [0000-0002-2198-8949], Apollo - University of Cambridge Repository, Blain, Alex E [0000-0001-8045-822X], Turner, Suzanne D [0000-0002-8439-4507], Burke, GA Amos [0000-0003-2671-9972], and Rand, Vikki [0000-0002-2198-8949]

Subjects
Male, Lymphoma, B-Cell, Adolescent, 45/61, Gene Dosage, article, Infant, 45/22, 45/77, 45/23, 631/67/69, 692/699/1541/1990/291/1621/1915, Genetic Loci, hemic and lymphatic diseases, Child, Preschool, Mutation, Disease Progression, Humans, Female, Tumor Suppressor Protein p53, Child, neoplasms
Abstract

Funder: RCUK | Medical Research Council (MRC); doi: https://doi.org/10.13039/501100000265, Funder: Good Will Cause, Funder: MRC/EPSRC Newcastle Pathology Node, Funder: Newcastle upon Tyne Hospitals NHS Foundation Trust (Newcastle upon Tyne Hospitals NHS Trust); doi: https://doi.org/10.13039/501100003776, Funder: Blood Cancer UK - Senior Bennett Fellowship #12005 North East Promenaders Against Cancer (NEPAC) The Little Princess Trust JGW Patterson Foundation, Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p = 0.002). Moreover, amongst patients clinically defined as high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53 abnormalities (PFS 100% vs 55.6%, p = 0.005, OS 100% vs 66.7%, p = 0.019). Biallelic TP53 abnormalities were either maintained from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities thus define clinical risk groups within paediatric B-NHL and offer a novel molecular risk stratifier, allowing more personalised treatment protocols.

Published
2020

6. The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia

Author

Furness, CL, Braga Mansur, M, Weston, VJ, Ermini, L, van Delft, FW, Jenkinson, S, Gale, R, Harrison, CJ, Pombo-de-Oliveira, MS, Sanchez-Martin, M, Ferrando, AA, Kearns, P, Titley, I, Ford, AM, Potter, NE, and Greaves, M

Subjects
Adult, Adolescent, Oncogene Proteins, Fusion, Intracellular Signaling Peptides and Proteins, PTEN Phosphohydrolase, Infant, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Polymorphism, Single Nucleotide, Article, Clonal Evolution, Disease Models, Animal, Young Adult, Cell Line, Tumor, Child, Preschool, Mutation, Animals, Heterografts, Humans, Single-Cell Analysis, Child, Multiplex Polymerase Chain Reaction, Alleles, In Situ Hybridization, Fluorescence, T-Cell Acute Lymphocytic Leukemia Protein 1, Genome-Wide Association Study
Abstract

Single-cell genetics were used to interrogate clonal complexity and the sequence of mutational events in STIL-TAL1+ T-ALL. Single-cell multicolour FISH was used to demonstrate that the earliest detectable leukaemia subclone contained the STIL-TAL1 fusion and copy number loss of 9p21.3 (CDKN2A/CDKN2B locus), with other copy number alterations including loss of PTEN occurring as secondary subclonal events. In three cases, multiplex qPCR and phylogenetic analysis were used to produce branching evolutionary trees recapitulating the snapshot history of T-ALL evolution in this leukaemia subtype, which confirmed that mutations in key T-ALL drivers, including NOTCH1 and PTEN, were subclonal and reiterative in distinct subclones. Xenografting confirmed that self-renewing or propagating cells were genetically diverse. These data suggest that the STIL-TAL1 fusion is a likely founder or truncal event. Therapies targeting the TAL1 auto-regulatory complex are worthy of further investigation in T-ALL.

Published
2018

16. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Author

Vijayakrishnan, J, Studd, J, Broderick, P, Kinnersley, B, Holroyd, A, Law, PJ, Kumar, R, Allan, JM, Harrison, CJ, Moorman, AV, Vora, A, Roman, E, Rachakonda, S, Kinsey, SE, Sheridan, E, Thompson, PD, Irving, JA, Koehler, R, Hoffmann, P, Nöthen, MM, Heilmann-Heimbach, S, Jöckel, KH, Easton, DF, Pharaoh, PDP, Dunning, AM, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Greaves, M, Zimmerman, M, Bartram, CR, Schrappe, M, Stanulla, M, Hemminki, K, Houlston, RS, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Olama, AAA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Maehle, L, Neal, DE, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, YJ, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, The PRACTICAL Consortium, and Claessens, Frank

Subjects
Male, Oncogene Proteins, Fusion, Glycosyltransferases, Prognosis, Polymorphism, Single Nucleotide, HLA Antigens, Risk Factors, Child, Preschool, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Core Binding Factor Alpha 2 Subunit, Humans, Female, Genetic Predisposition to Disease, Child, Genome-Wide Association Study
Abstract

© 2018 The Author(s). Genome-wide association studies (GWAS) have advanced our understanding of susceptibility to B-cell precursor acute lymphoblastic leukemia (BCP-ALL); however, much of the heritable risk remains unidentified. Here, we perform a GWAS and conduct a meta-analysis with two existing GWAS, totaling 2442 cases and 14,609 controls. We identify risk loci for BCP-ALL at 8q24.21 (rs28665337, P = 3.86 × 10-9, odds ratio (OR) = 1.34) and for ETV6-RUNX1 fusion-positive BCP-ALL at 2q22.3 (rs17481869, P = 3.20 × 10-8, OR = 2.14). Our findings provide further insights into genetic susceptibility to ALL and its biology. ispartof: Nature Communications vol:9 issue:1 ispartof: location:England status: published

Published
2018

17. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (vol 9, 1340, 2018)

Author

Vijayakrishnan, J, Studd, J, Broderick, P, Kinnersley, B, Holroyd, A, Law, PJ, Kumar, R, Allan, JM, Harrison, CJ, Moorman, AV, Vora, A, Roman, E, Rachakonda, S, Kinsey, SE, Sheridan, E, Thompson, PD, Irving, JA, Koehler, R, Hoffmann, P, Noethen, MM, Heilmann-Heimbach, S, Joeckel, K-H, Easton, DF, Pharaoh, PDP, Dunning, AM, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Maehle, L, Neal, DE, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Greaves, M, Zimmerman, M, Bartram, CR, Schrappe, M, Stanulla, M, Hemminki, K, Houlston, RS, Vijayakrishnan, J, Studd, J, Broderick, P, Kinnersley, B, Holroyd, A, Law, PJ, Kumar, R, Allan, JM, Harrison, CJ, Moorman, AV, Vora, A, Roman, E, Rachakonda, S, Kinsey, SE, Sheridan, E, Thompson, PD, Irving, JA, Koehler, R, Hoffmann, P, Noethen, MM, Heilmann-Heimbach, S, Joeckel, K-H, Easton, DF, Pharaoh, PDP, Dunning, AM, Peto, J, Canzian, F, Swerdlow, A, Eeles, RA, Kote-Jarai, Z, Muir, K, Pashayan, N, Henderson, BE, Haiman, CA, Benlloch, S, Schumacher, FR, Al Olama, AA, Berndt, SI, Conti, DV, Wiklund, F, Chanock, S, Stevens, VL, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Schleutker, J, Albanes, D, Weinstein, S, Wolk, A, West, C, Mucci, L, Cancel-Tassin, G, Koutros, S, Sorensen, KD, Maehle, L, Neal, DE, Travis, RC, Hamilton, RJ, Ingles, SA, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, John, EM, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Greaves, M, Zimmerman, M, Bartram, CR, Schrappe, M, Stanulla, M, Hemminki, K, and Houlston, RS

Abstract

The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected in both the PDF and HTML versions of the Article. Furthermore, in the original HTML version of this Article, the order of authors within the author list was incorrect. The PRACTICAL consortium was incorrectly listed after Richard S. Houlston and should have been listed after Nora Pashayan. This error has been corrected in the HTML version of the Article; the PDF version was correct at the time of publication.

Published
2019

19. Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia

Author

O'Connor, D, Enshaei, A, Bartram, J, Hancock, J, Harrison, CJ, Hough, R, Samarasinghe, S, Schwab, C, Vora, A, Wade, R, Moppett, J, Moorman, AV, and Goulden, N

Subjects
body regions, hemic and lymphatic diseases
Abstract

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize MRD data and do not assimilate genetics when assigning MRD risk, which reduces predictive accuracy. The aim of our study was to exploit the full power of MRD by examining it as a continuous variable and to integrate it with genetics. Patients and Methods We used a population-based cohort of 3,113 patients who were treated in UKALL2003, with a median follow-up of 7 years. MRD was evaluated by polymerase chain reaction analysis of Ig/TCR gene rearrangements, and patients were assigned to a genetic subtype on the basis of immunophenotype, cytogenetics, and fluorescence in situ hybridization. To examine response kinetics at the end of induction, we log-transformed the absolute MRD value and examined its distribution across subgroups. Results MRD was log normally distributed at the end of induction. MRD distributions of patients with distinct genetic subtypes were different (P < .001). Patients with good-risk cytogenetics demonstrated the fastest disease clearance, whereas patients with high-risk genetics and T-cell acute lymphoblastic leukemia responded more slowly. The risk of relapse was correlated with MRD kinetics, and each log reduction in disease level reduced the risk by 20% (hazard ratio, 0.80; 95% CI, 0.77 to 0.83; P < .001). Although the risk of relapse was directly proportional to the MRD level within each genetic risk group, absolute relapse rate that was associated with a specific MRD value or category varied significantly by genetic subtype. Integration of genetic subtype–specific MRD values allowed more refined risk group stratification. Conclusion A single threshold for assigning patients to an MRD risk group does not reflect the response kinetics of the different genetic subtypes. Future risk algorithms should integrate genetics with MRD to accurately identify patients with the lowest and highest risk of relapse.

Published
2017

25. Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups

Author

Attarbaschi, A, Morak, M, Cario, G, Cazzaniga, G, Ensor, Hm, TE KRONNIE, Geertrudy, Bradtke, J, Mann, G, Vendramini, E, Palmi, C, Schwab, C, Russell, Lj, Schrappe, M, Conter, V, Mitchell, Cd, Strehl, S, Zimmermann, M, Pötschger, U, Harrison, Cj, Stanulla, M, Panzer Grümayer, R, Haas, Oa, Moorman, Av, Associazione Italiana di Ematologia ed Oncologia Pediatrica Berlin Frankfurt Münster Study Group, National Cancer Research Institute Children's Cancer, Leukaemia Study Group, Attarbaschi, A, Morak, M, Cario, G, Cazzaniga, G, Ensor, H, te Kronnie, T, Bradtke, J, Mann, G, Vendramini, E, Palmi, C, Schwab, C, Russell, L, Schrappe, M, Conter, V, Mitchell, C, Strehl, S, Zimmermann, M, Pötschger, U, Harrison, C, Stanulla, M, Panzer Grümayer, R, Haas, O, and Moorman, A

Subjects
Male, Risk, medicine.medical_specialty, Pediatrics, Study groups, Adolescent, Treatment outcome, Kaplan-Meier Estimate, Acute leukaemia, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Genetics, medicine, Humans, Multicenter Studies as Topic, Receptors, Cytokine, Child, Randomized Controlled Trials as Topic, business.industry, Incidence (epidemiology), Remission Induction, Childhood leukaemia, Infant, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Europe, Treatment Outcome, Child, Preschool, Lymphoblastic leukaemia, Female, business, Follow-Up Studies
Abstract

The prognostic relevance of CRLF2 -rearrangements in childhood acute B-cell precursor lymphoblastic leukaemia (ALL), was assessed by a comparative analysis of 114 non-Down-syndrome patients (99 P2RY8-CRLF2+ , 15 IGH@-CRLF2+ ), 76 from the AIEOP-BFM ALL 2000 and 38 from the MRC ALL97 trials. The 6-year cumulative relapse incidence of P2RY8-CRLF2+ patients treated on the two trials was not statistically different: 0·37 ± 0·06 vs. 0·25 ± 0·08 (P = 0·194). In contrast, 0/9 IGH@-CRLF2+ AIEOP-BFM, but 5/6 ALL97 patients relapsed. Conclusively, P2RY8-CRLF2+ patients had an intermediate protocol-independent outcome while the different prognosis of IGH@-CRLF2+ patients could be related to the different structures of the applied treatment protocols.

Published
2012

27. Potential of in vivo real-time gastric gas profiling: A pilot evaluation of heat-stress and modulating dietary cinnamon effect in an animal model

Author

Ou, JZ, Cottrell, JJ, Ha, N, Pillai, N, Yao, CK, Berean, KJ, Ward, SA, Grando, D, Muir, JG, Harrison, CJ, Wijesiriwardana, U, Dunshea, FR, Gibson, PR, Kalantar-Zadeh, K, Ou, JZ, Cottrell, JJ, Ha, N, Pillai, N, Yao, CK, Berean, KJ, Ward, SA, Grando, D, Muir, JG, Harrison, CJ, Wijesiriwardana, U, Dunshea, FR, Gibson, PR, and Kalantar-Zadeh, K

Abstract

Gastroenterologists are still unable to differentiate between some of the most ordinary disorders of the gut and consequently patients are misdiagnosed. We have developed a swallowable gas sensor capsule for addressing this. The gases of the gut are the by-product of the fermentation processes during digestion, affected by the gut state and can consequently provide the needed information regarding the health of the gut. Here we present the first study on gas sensor capsules for revealing the effect of a medical supplement in an animal (pig) model. We characterise the real-time alterations of gastric-gas in response to environmental heat-stress and dietary cinnamon and use the gas profiles for understanding the bio-physiological changes. Under no heat-stress, feeding increases gastric CO2 concentration, while dietary cinnamon reduces it due to decrease in gastric acid and pepsin secretion. Alternatively, heat-stress leads to hyperventilation in pigs, which reduces CO2 concentration and with the cinnamon treatment, CO2 diminishes even more, resulting in health improvement outcomes. Overall, a good repeatability in gas profiles is also observed. The model demonstrates the strong potential of real-time gas profiler in providing new physiological information that will impact understanding of therapeutics, presenting a highly reliable device for monitoring/diagnostics of gastrointestinal disorders.

Published
2016

28. PHF6 mutations in T-cell lymphoblastic leukemia

Author

Vlierberghe, P, Palomero, T, Khiabanian, H, van der Meulen, J, Castillo, M, van Roy, N, de Moerloose, B, Philippe, J, Conzalez-Garcia, S, Toribio, ML, Taghon, T, Zuurbier, Linda, Cauwelier, B, Harrison, CJ, Schwab, C, Pisecker, M, Strehl, S, Langerak, Ton, Gecz, J, Sonneveld, E, Pieters, Rob, Paietta, E, Rowe, J, Wiernik, PH, Benoit, Y, Soulier, J, Poppe, B, Yao, X, Cordon-Cardo, C, Meijerink, Jules, Rabadan, R, Speleman, F, Ferrando, AA, Pediatrics, and Immunology

Published
2010

29. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements

Author

De Lorenzo, P, Moorman, A, Pieters, R, Dreyer, Z, Heerema, N, Carroll, A, Hunger, S, Harvey, R, Willman, C, Devidas, M, Valsecchi, M, Harrison, C, Moorman, AV, Dreyer, ZE, Heerema, NA, Carroll, AJ, Hunger, SP, Willman, CL, Valsecchi, MG, Harrison, CJ, De Lorenzo, P, Moorman, A, Pieters, R, Dreyer, Z, Heerema, N, Carroll, A, Hunger, S, Harvey, R, Willman, C, Devidas, M, Valsecchi, M, Harrison, C, Moorman, AV, Dreyer, ZE, Heerema, NA, Carroll, AJ, Hunger, SP, Willman, CL, Valsecchi, MG, and Harrison, CJ

Published
2014

30. t(6;9)(p22; q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients

Author

Sandahl, JD, Coenen, Eva, Forestier, E, Harbott, J, Johansson, B, Kerndrup, G, Adachi, S, Auvrignon, A, Beverloo, Berna, Cayuela, JM, Chilton, L, Fornerod, M, de Haas, V, Harrison, CJ, Inaba, H, Kaspers, GJL, Liang, DC, Locatelli, F (Franco), Masetti, R, Perot, C, Raimondi, SC, Reinhardt, K, Tomizawa, D, von Neuhoff, N, Zecca, M, Zwaan, CM, Eibrink, Marry, Hasle, H, Sandahl, JD, Coenen, Eva, Forestier, E, Harbott, J, Johansson, B, Kerndrup, G, Adachi, S, Auvrignon, A, Beverloo, Berna, Cayuela, JM, Chilton, L, Fornerod, M, de Haas, V, Harrison, CJ, Inaba, H, Kaspers, GJL, Liang, DC, Locatelli, F (Franco), Masetti, R, Perot, C, Raimondi, SC, Reinhardt, K, Tomizawa, D, von Neuhoff, N, Zecca, M, Zwaan, CM, Eibrink, Marry, and Hasle, H

Published
2014

31. Identification of novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia

Author

Balgobind, BV, Raimondi, SC, Harbott, J, Zimmermann, M, Alonzo, TA, Auvrignon, A, Beverloo, HB, Chang, M, Creutzig, U, Dworzak, MN, Forestier, E, Gibson, B, Hasle, Henrik, Harrison, CJ, Heerema, NA, Kaspers, GJ, Leszl, A, Litvinko, N, Nigro, LL, Morimoto, A, Perot, C, Pieters, R, Reinhardt, D, Rubnitz, JE, Smith, FO, Stary, J, Stasevich, I, Strehl, S, Taga, T, Tomizawa, D, Webb, D, Zemanova, Z, Zwaan, CM, and van den Heuvel-Eibrink, MM

Published
2009

33. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group. Biology and Diagnosis Committee of International Berlin-Frankfürt-Münster study group

Author

Harrison, C, Haas, O, Harbott, J, Biondi, A, Stanulla, M, Trka, J, Izraeli, S, Harrison, CJ, Izraeli, S., BIONDI, ANDREA, Harrison, C, Haas, O, Harbott, J, Biondi, A, Stanulla, M, Trka, J, Izraeli, S, Harrison, CJ, Izraeli, S., and BIONDI, ANDREA

Abstract

Treatment of childhood acute lymphoblastic leukaemia (ALL) has improved considerably in recent years. A contributing factor has been the improved stratification for treatment according to a number of factors, including genetic determinants of outcome. Here we review the current diagnostic criteria of genetic abnormalities in precursor B-ALL (BCP-ALL), including the relevant technical approaches and the application of the most appropriate methods for the detection of each abnormality. The abnormalities with the most significant impact for treatment and management of BCP-ALL are t(9;22)(q34;q11)/BCR-ABL1, t(4;11)(q21;q23)/MLL-AFF1 and near-haploidy/low hypodiploidy for high risk stratification and, to a lesser extent, t(12;21)(p13;q22)/ETV6-RUNX1 and high hyperdiploidy for good risk management. Apart from the numerical abnormalities, these can be routinely tested for by reverse transcription polymerase chain reaction, providing a basic yet informative screen. However, cytogenetics, particularly fluorescence in situ hybridization may provide reliable alternative detection methods dependent upon the preferred technical approach within each protocol. © 2010 Blackwell Publishing Ltd.

Published
2010

35. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities

Author

Moorman, AV, Raimondi, SC, Pui, CH, Baruchel, A, Biondi, A, Carroll, AJ, Forestier, Erik, Gaynon, PS, Harbott, J, Harms, DO, Heerema, N, Pieters, R, Schrappe, M, Silverman, LB, Vilmer, E, Harrison, CJ, Moorman, AV, Raimondi, SC, Pui, CH, Baruchel, A, Biondi, A, Carroll, AJ, Forestier, Erik, Gaynon, PS, Harbott, J, Harms, DO, Heerema, N, Pieters, R, Schrappe, M, Silverman, LB, Vilmer, E, and Harrison, CJ

Abstract

This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia ( ALL) and examined the impact of these ACA on survival. Overall, 213 (47%) cases had ACA but the incidence varied according to patient age and 11q23 subgroup. Infants and patients with t(4; 11)(q21; q23) had the lowest incidence of ACA (50/182 (27%) and 57/216 (26%) respectively), whereas patients with del( 11)( q23) had the highest incidence (66/93 (71%)). Del( 11)( q23) abnormalities were heterogeneous and occasionally secondary to t( 9; 22)(q34; q11.2). Thus, patients with del( 11)( q23) comprised a separate biological entity, which was clearly distinct from those with an 11q23 translocation. The most frequent specific ACA were trisomy X ( n = 38), abnormal 12p ( n = 32), abnormal 9p ( n = 28) and del( 6q) ( n = 19). The presence of ACA did not change the 5 year event-free survival estimates among children (56% (95% CI 46 - 65%) vs 62% (54 - 69%)) or infants (22% ( 15 - 29%) vs 18% ( 9 - 29%)), nor when the different 11q23 subgroups were analyzed separately. This study has conclusively demonstrated that there is no prognostic effect of secondary chromosomal changes in association with 11q23 abnormalities in childhood ALL. However, characterization of these ACA is important to determine their potential role in initiation of MLL driven leukemogenesis.

Published
2005
Full Text
View/download PDF

36. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities

Author

Moorman, A, Raimondi, S, Pui, C, Baruchel, A, Biondi, A, Carroll, A, Forestier, E, Gaynon, P, Harbott, J, Harms, D, Heerema, N, Pieters, R, Schrappe, M, Silverman, L, Vilmer, E, Harrison, C, Moorman, AV, Raimondi, SC, Pui, CH, Carroll, AJ, Gaynon, PS, Harms, DO, Silverman, LB, Harrison, CJ, BIONDI, ANDREA, Moorman, A, Raimondi, S, Pui, C, Baruchel, A, Biondi, A, Carroll, A, Forestier, E, Gaynon, P, Harbott, J, Harms, D, Heerema, N, Pieters, R, Schrappe, M, Silverman, L, Vilmer, E, Harrison, C, Moorman, AV, Raimondi, SC, Pui, CH, Carroll, AJ, Gaynon, PS, Harms, DO, Silverman, LB, Harrison, CJ, and BIONDI, ANDREA

Abstract

This study characterized the additional chromosomal abnormalities (ACA) associated with 11q23 rearrangements in 450 infants and children with acute lymphoblastic leukemia (ALL) and examined the impact of these ACA on survival. Overall, 213 (47%) cases had ACA but the incidence varied according to patient age and 11q23 subgroup. Infants and patients with t(4;11)(q21;q23) had the lowest incidence of ACA (50/182 (27%) and 57/216 (26%) respectively), whereas patients with del(11)(q23) had the highest incidence (66/93 (71%)). Del(11)(q23) abnormalities were heterogeneous and occasionally secondary to t(9;22)(q34;q11.2). Thus, patients with del(11)(q23) comprised a separate biological entity, which was clearly distinct from those with an 11q23 translocation. The most frequent specific ACA were trisomy X (n = 38), abnormal 12p (n = 32), abnormal 9p (n = 28) and del(6q) (n = 19). The presence of ACA did not change the 5 year event-free survival estimates among children (56% (95% Cl 46-65%) vs 62% (54-69%)) or infants (22% (15-29%) vs 18% (9-29%)), nor when the different 11q23 subgroups were analyzed separately. This study has conclusively demonstrated that there is no prognostic effect of secondary chromosomal changes in association with 11q23 abnormalities in childhood ALL. However, characterization of these ACA is important to determine their potential role in initiation of MLL driven leukemogenesis.

Published
2005

37. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome

Author

Heerema, N, Harbott, J, Galimberti, S, Camitta, B, Gaynon, P, Janka Schaub, G, Kamps, W, Basso, G, Pui, C, Schrappe, M, Auclerc, M, Carroll, A, Conter, V, Harrison, C, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sather, H, Shuster, J, Silverman, L, Valsecchi, M, Heerema, NA, Camitta, BM, Gaynon, PS, Pui, CH, Auclerc, MF, Carroll, AJ, Harrison, CJ, Raimondi, SC, Sather, HN, Shuster, JJ, Silverman, LB, GALIMBERTI, STEFANIA, VALSECCHI, MARIA GRAZIA, Heerema, N, Harbott, J, Galimberti, S, Camitta, B, Gaynon, P, Janka Schaub, G, Kamps, W, Basso, G, Pui, C, Schrappe, M, Auclerc, M, Carroll, A, Conter, V, Harrison, C, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sather, H, Shuster, J, Silverman, L, Valsecchi, M, Heerema, NA, Camitta, BM, Gaynon, PS, Pui, CH, Auclerc, MF, Carroll, AJ, Harrison, CJ, Raimondi, SC, Sather, HN, Shuster, JJ, Silverman, LB, GALIMBERTI, STEFANIA, and VALSECCHI, MARIA GRAZIA

Abstract

Additional chromosomal aberrations occur frequently in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) of childhood. The treatment outcome of these patients is heterogeneous. This study assessed whether such clinical heterogeneity could be partially explained by the presence and characteristics of additional chromosomal abnormalities. Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996. Secondary aberrations were present in 61% of the cases. Chromosomes 9, 22, 7, 14, and 8 were most frequently abnormal. Most (93%) karyotypes were unbalanced. Three main cytogenetic subgroups were identified: no secondary aberrations, gain of a second Ph and/or >50 chromosomes, or loss of chromosome 7, 7p, and/or 9p, while other secondary aberrations were grouped as combinations of gain and loss or others. Of the three main cytogenetic subgroups, the loss group had the worst event-free survival (P=0.124) and disease-free survival (P=0.013). However, statistical significance was not maintained when adjusted for other prognostic factors and treatment. Karyotypic analysis is valuable in subsets of patients identified by molecular screening, to assess the role of additional chromosomal abnormalities and their correlation with clinical heterogeneity, with possible therapeutic implications.

Published
2004

39. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements

Author

Pui, C, Chessells, J, Camitta, B, Baruchel, A, Biondi, A, Boyett, J, Carroll, A, Eden, O, Evans, W, Gadner, H, Harbott, J, Harms, D, Harrison, C, Harrison, P, Heerema, N, Janka Schaub, G, Kamps, W, Masera, G, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sallan, S, Sather, H, Shuster, J, Silverman, L, Valsecchi, M, Vilmer, E, Zhou, Y, Gaynon, P, Schrappe, M, Chessells, JM, BIONDI, ANDREA, Boyett, JM, Eden, OB, Evans, WE, Harms, DO, Harrison, CJ, Harrison, PL, Raimondi, SC, Silverman, LB, Gaynon, PS, Schrappe, M., VALSECCHI, MARIA GRAZIA, Pui, C, Chessells, J, Camitta, B, Baruchel, A, Biondi, A, Boyett, J, Carroll, A, Eden, O, Evans, W, Gadner, H, Harbott, J, Harms, D, Harrison, C, Harrison, P, Heerema, N, Janka Schaub, G, Kamps, W, Masera, G, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sallan, S, Sather, H, Shuster, J, Silverman, L, Valsecchi, M, Vilmer, E, Zhou, Y, Gaynon, P, Schrappe, M, Chessells, JM, BIONDI, ANDREA, Boyett, JM, Eden, OB, Evans, WE, Harms, DO, Harrison, CJ, Harrison, PL, Raimondi, SC, Silverman, LB, Gaynon, PS, Schrappe, M., and VALSECCHI, MARIA GRAZIA

Abstract

To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single institutions. The substantial sample size allowed separate analyses according to age younger or older than 12 months for the various cytogenetic subsets. Infants with t(4;11) ALL had an especially dismal prognosis when their disease was characterized by a poor early response to prednisone (P=0.0005 for overall comparison; 5-year event-free survival (EFS), 0 vs 23+/-+/-12% s.e. for those with good response), or age less than 3 months (P=0.0003, 5-year EFS, 5+/-+/-5% vs 23.4+/-+/-4% for those over 3 months). A poor prednisone response also appeared to confer a worse outcome for older children with t(4;11) ALL. Hematopoietic stem cell transplantation failed to improve outcome in either age group. Among patients with t(11;19) ALL, those with a T-lineage immunophenotype, who were all over 1 year of age, had a better outcome than patients over 1 year of age with B-lineage ALL (overall comparison, P=0.065; 5-year EFS, 88+/-+/-13 vs 46+/-14%). In the heterogeneous subgroup with del(11)(q23), National Cancer Institute-Rome risk criteria based on age and leukocyte count had prognostic significance (P=0.04 for overall comparison; 5-year EFS, 64+/-+/-8% (high risk) vs 83+/-+/-6% (standard risk)). This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy

Published
2003

43. Battling drug-resistant Streptococcus pneumoniae in children.

Author

Harrison CJ, Pong A, and Lucas BD

Abstract

Pneumonococci are resistant to several commonly used antibiotics. Selecting an appropriate agent can be a clinical puzzle. With the right information and a systematic approach, you can devise an effective strategy for dealing with this organism in your community. [ABSTRACT FROM AUTHOR]

Published
1999

45. How will the new guideline for managing otitis media work in your practice?

Author

Harrison CJ

Abstract

The first round of recommendations from two expert groups illuminates several areas: diagnostic criteria, pain management, observational management, and the use--or withholding-of initial antibiotics. But the advice covers only a segment of acute otitis media patients, and some key areas of care aren't addressed--yet. Here is a sweeping review of what the guideline might mean for the kind of care you give. [ABSTRACT FROM AUTHOR]

Published
2004

46. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study

Author

Andrea Pession, Batia Stark, Shai Izraeli, Christine J. Harrison, Kyra Michalova, Oskar A. Haas, Erik Forestier, Bertil Johansson, Bernal Beverloo, Andrea Teigler-Schlegel, Clinical Genetics, Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, Stark B, Harrison CJ, Teigler-Schlegel A, and Johansson B.

Subjects
Adult, Male, medicine.medical_specialty, Myeloid, Adolescent, Immunology, Aneuploidy, Biochemistry, Cytogenetics, Acute lymphocytic leukemia, hemic and lymphatic diseases, medicine, Chromosomes, Human, Humans, Child, Chromosome Aberrations, business.industry, Genome, Human, Infant, Newborn, Myeloid leukemia, Infant, Cell Biology, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Child, Preschool, Karyotyping, dup, Female, Hyperdiploidy, Down Syndrome, business
Abstract

Children with Down syndrome (DS) have a markedly increased risk of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). To identify chromosomal changes cooperating with +21 that may provide information on the pathogenesis of these leukemias, we analyzed 215 DS-ALLs and 189 DS-AMLs. Unlike previous smaller series, a significant proportion of DS-ALLs had the typical B-cell precursor ALL abnormalities high hyperdiploidy (HeH; 11%) and t(12;21)(p13;q22) (10%). The HeH DS-ALLs were characterized by gains of the same chromosomes as non–DS-HeH, suggesting the same etiology/pathogenesis. In addition, specific genetic subtypes of DS-ALL were suggested by the significant overrepresentation of cases with +X, t(8;14)(q11;q32), and del(9p). Unlike DS-ALL, the common translocations associated with non–DS-AML were rare in DS-AML, which instead were characterized by the frequent presence of dup(1q), del(6q), del(7p), dup(7q), +8, +11, del(16q), and +21. This series of DS leukemias—the largest to date—reveals that DS-ALL is a heterogeneous disorder that comprises both t(12;21) and HeH as well as DS-related abnormalities. Furthermore, this analysis confirms that DS-AML is a distinct entity, originating through other genetic pathways than do non–DS-AMLs, and suggests that unbalanced changes such as dup(1q), +8, and +21 are involved in the leukemogenic process.

Published
2008

47. t(6;9)(p22;q34)/DEK-NUP214 rearranged pediatric myeloid leukemia: an international study on 62 patients

Author

Jean Michel Cayuela, Daisuke Tomizawa, Jochen Harbott, Der Cherng Liang, Christine Perot, Valerie de Haas, Nils von Neuhoff, Anne Auvrignon, Hiroto Inaba, Susana C. Raimondi, C. Michel Zwaan, Gertjan J.L. Kaspers, Christine J. Harrison, Gitte Kerndrup, Franco Locatelli, Marco Zecca, Souichi Adachi, Julie Damgaard Sandahl, Erik Forestier, Riccardo Masetti, Katarina Reinhardt, Lucy Chilton, Bertil Johansson, Maarten Fornerod, Marry M. van den Heuvel-Eibrink, Henrik Hasle, Eva A. Coenen, H. Berna Beverloo, Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi S, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H, Erasmus MC other, Clinical Genetics, Pediatrics, Pediatric surgery, and CCA - Innovative therapy

Subjects
Oncology, Male, medicine.medical_specialty, Myeloid, Adolescent, Oncogene Proteins, Fusion, Chromosomal Proteins, Non-Histone, medicine.medical_treatment, Hematopoietic stem cell transplantation, Translocation, Genetic, Bone Marrow, Recurrence, Internal medicine, hemic and lymphatic diseases, medicine, Humans, Cumulative incidence, Child, Poly-ADP-Ribose Binding Proteins, Oncogene Proteins, Hematology, business.industry, Myelodysplastic syndromes, Gene Expression Profiling, Childhood Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation, Infant, Newborn, Myeloid leukemia, Infant, Articles, ACUTE NONLYMPHOCYTIC LEUKEMIA, TUMOR-SUPPRESSOR, GROWTH ARREST, PROTEIN DEK, FG REPEATS, PR DOMAIN, GENE, EXPRESSION, MALIGNANCIES, FUSION, medicine.disease, Nuclear Pore Complex Proteins, Leukemia, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Treatment Outcome, N/A, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Leukemia, Myeloid, Child, Preschool, Myelodysplastic Syndromes, Immunology, Chromosomes, Human, Pair 6, Female, business, Chromosomes, Human, Pair 9
Abstract

Acute myeloid leukemia with t(6;9)(p22;q34) is listed as a distinct entity in the 2008 World Health Organization classification, but little is known about the clinical implications of t(6;9)-positive myeloid leukemia in children. This international multicenter study presents the clinical and genetic characteristics of 62 pediatric patients with t(6;9)/DEK-NUP214-rearranged myeloid leukemia; 54 diagnosed as having acute myeloid leukemia, representing

Published
2014

48. On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.

Author

Hofstetter AM, Klein EJ, Strelitz B, Selvarangan R, Schuster JE, Boom JA, Sahni LC, Halasa NB, Stewart LS, Staat MA, Rohlfs C, Szilagyi PG, Weinberg GA, Williams JV, Michaels MG, Moline H, Mirza SA, Harrison CJ, and Englund JA

Abstract

Background: The COVID-19 pandemic raised unprecedented challenges to vaccinating children. This multi-center study aimed to compare on-time vaccination of children before and during the COVID-19 pandemic and identify key factors associated with on-time vaccination., Methods: This study was conducted among children aged 0-6 years enrolled in the New Vaccine Surveillance Network at seven geographically diverse U.S. academic medical centers. Children with acute respiratory illness or acute gastroenteritis were enrolled from emergency department and inpatient settings; healthy control subjects were enrolled from primary care practices. Vaccination data were collected and verified from patient medical records, immunization information systems, and/or provider documentation. On-time vaccination according to Advisory Committee on Immunization Practices recommendations was compared between pre-pandemic (December 2018-February 2020) and pandemic (March 2020-August 2021) periods using bivariate and multivariable analyses, adjusting for key demographic, clinical, and study characteristics., Results: A total of 24,713 children were included in the analytic sample (non-Hispanic 73.4 %; White 51.0 %; publicly insured 69.0 %). On-time vaccination declined between the pre-pandemic (67.3 %) and pandemic (65.4 %) periods (Adjusted Odds Ratio 0.89, 95 % CI 0.84-0.95). The largest declines were observed among children who were < 12 months, male, Black, publicly insured, or whose mothers had a high school-equivalent education or less. The pandemic impact also varied by vaccine type and study site., Conclusions: This multi-center study revealed a relatively modest overall reduction in on-time vaccination, which may reflect multilevel efforts to address pandemic-associated challenges. However, some patient subgroups and sites experienced greater reductions in on-time vaccination, highlighting the importance of tailoring interventions to increase equitable vaccine delivery, access, and acceptance across populations and communities., Competing Interests: Declaration of competing interest N.B.H.: Research funding from Sanofi, Quidel, and Merck. M.A.S.: Institutional funding from the Centers for Disease Control and Prevention, National Institutes of Health, and Cepheid for respiratory virus testing. Research funding from Merck. Funding from Up-To-Date for article preparation. Funding from the American Academy of Pediatrics for ID course preparation. G.A.W.: Received honoraria from Merck & Co for writing and editing chapters in the Merck Manual textbook. J.V.W.: Previously served within last 3 years on a Scientific Advisory Board for Quidel and Independent Data Monitoring Committee for GlaxoSmithKline. C.J.H.: Research funding from GSK, Pfizer, and Merck through June 30, 2022. J.A.E.: Institutional funding from AstraZeneca, Merck, GlaxoSmithKline, and Pfizer. Consultant for Abbvie, AstraZeneca, Meissa Vaccines, Moderna, Pfizer, and SanofiPasteur. The other authors have no financial relationships or potential conflicts of interest to disclose., (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Published
2024
Full Text
View/download PDF

49. Pediatric Clinical Influenza Disease by Type and Subtype 2015-2020: A Multicenter, Prospective Study.

Author

Grioni HM, Sullivan E, Strelitz B, Lacombe K, Klein EJ, Boom JA, Sahni LC, Michaels MG, Williams JV, Halasa NB, Stewart LS, Staat MA, Schlaudecker EP, Selvarangan R, Harrison CJ, Schuster JE, Weinberg GA, Szilagyi PG, Singer MN, Azimi PH, Clopper BR, Moline HL, Campbell AP, Olson SM, and Englund JA

Abstract

Background: Previous investigations into clinical signs and symptoms associated with influenza types and subtypes have not definitively established differences in the clinical presentation or severity of influenza disease., Methods: The study population included children 0 through 17 years old enrolled at 8 New Vaccine Surveillance Network sites between 2015 and 2020 who tested positive for influenza virus by molecular testing. Demographic and clinical data were collected for study participants via parent/guardian interview and medical chart review. Descriptive statistics were used to summarize demographic and clinical characteristics by influenza subtype. Multivariable logistic regression and Cox proportional hazard models were used to assess effects of age, sex, influenza subtype, and history of asthma on severity, including hospital admission, need for supplemental oxygen, and length of stay., Results: Retractions, cyanosis, and need for supplemental oxygen were more frequently observed among patients with influenza A(H1N1)pdm09. Headaches and sore throat were more commonly reported among patients with influenza B. Children with influenza A(H1N1)pdm09 and children with asthma had significantly increased odds of hospital admission (adjusted odds ratio (AOR): 1.39, 95% CI: 1.14-1.69 and AOR: 2.14, 95% CI: 1.72-2.67, respectively). During admission, children with influenza A(H1N1)pdm09 had significantly increased use of supplemental oxygen compared to children with A(H3N2) (AOR: 0.60, 95% CI: 0.44-0.82) or B (AOR: 0.56, 95% CI: 0.41-0.76)., Conclusions: Among children presenting to the emergency department and admitted to the hospital, influenza A(H1N1)pdm09 caused more severe disease compared to influenza A(H3N2) and influenza B. Asthma also contributed to severe influenza disease regardless of subtype., (Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2024. This work is written by (a) US Government employee(s) and is in the public domain in the US.)

Published
2024
Full Text
View/download PDF

50. Rotavirus Vaccine Effectiveness Against Severe Acute Gastroenteritis: 2009-2022.

Author

Diallo AO, Wikswo ME, Sulemana I, Sahni LC, Boom JA, Ramani S, Selvarangan R, Moffatt ME, Harrison CJ, Halasa N, Chappell J, Stewart L, Staat MA, Schlaudecker E, Quigley C, Klein EJ, Englund JA, Zerr DM, Weinberg GA, Szilagyi PG, Albertin C, Johnston SH, Williams JV, Michaels MG, Hickey RW, Curns AT, Honeywood M, Mijatovic-Rustempasic S, Esona MD, Bowen MD, Parashar UD, Gautam R, Mirza SA, and Tate JE

Subjects
Humans, Infant, Child, Preschool, Male, Female, Case-Control Studies, Acute Disease, United States epidemiology, Severity of Illness Index, Rotavirus immunology, Hospitalization statistics & numerical data, Rotavirus Vaccines immunology, Rotavirus Vaccines therapeutic use, Rotavirus Vaccines administration & dosage, Gastroenteritis prevention & control, Gastroenteritis virology, Gastroenteritis epidemiology, Rotavirus Infections prevention & control, Rotavirus Infections epidemiology, Vaccine Efficacy
Abstract

Background: Rotavirus was the leading cause of acute gastroenteritis among US children until vaccine introduction in 2006, after which, substantial declines in severe rotavirus disease occurred. We evaluated rotavirus vaccine effectiveness (VE) over 13 years (2009-2022)., Methods: We analyzed data from the New Vaccine Surveillance Network using a test-negative case-control design to estimate rotavirus VE against laboratory-confirmed rotavirus infections among children seeking care for acute gastroenteritis (≥3 diarrhea or ≥1 vomiting episodes within 24 hours) in the emergency department (ED) or hospital. Case-patients and control-patients were children whose stool specimens tested rotavirus positive or negative, respectively, by enzyme immunoassay or polymerase chain reaction assays. VE was calculated as (1-adjusted odds ratio)×100%. Adjusted odds ratios were calculated by multivariable unconditional logistic regression., Results: Among 16 188 enrolled children age 8 to 59 months, 1720 (11%) tested positive for rotavirus. Case-patients were less often vaccinated against rotavirus than control-patients (62% versus 88%). VE for receiving ≥1 dose against rotavirus-associated ED visits or hospitalization was 78% (95% confidence interval [CI] 75%-80%). Stratifying by a modified Vesikari Severity Score, VE was 59% (95% CI 49%-67%), 80% (95% CI 77%-83%), and 94% (95% CI 90%-97%) against mild, moderately severe, and very severe disease, respectively. Rotavirus vaccines conferred protection against common circulating genotypes (G1P[8], G2P[4], G3P[8], G9P[8], and G12[P8]). VE was higher in children <3 years (73% to 88%); protection decreased as age increased., Conclusions: Rotavirus vaccines remain highly effective in preventing ED visits and hospitalizations in US children., (Copyright © 2024 by the American Academy of Pediatrics.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results